After falling 17 per cent since the start of the year to its March lows, the stock of the country’s largest pharmaceutical ...

Deal-making news last week included US drug developer KalVista Pharma signing a licensing agreement with Kaken Pharma to market its investigational hereditary angioedema (HAE) drug sebetralstat in ...

A special congressional committee has recommended a $15 billion investment to boost the United States' biotech advantage over ...

Indian drugmaker Sun (BSE: 524715) shares were buzzing in trade on the last trading day of the week to April 11, rising as ...

According to market estimates, Leqselvi is projected to contribute $90 million to Sun Pharma's sales in FY26, and $125 ...

Emkay Global Financial is bullish on Sun Pharma has recommended buy rating on the stock with a target price of Rs 2400 in its ...

Emkay Global Financial Services, in a client note, described the development as “materially positive,” as it removes a key ...

Emkay Global maintains a 'Buy' rating on Sun Pharma after the US Court of Appeals vacates the injunction against Leqselvi's ...

Sun Pharma stock rose more than 5 per cent intraday on Friday, April 11, after the company got a favorable order from a US ...

Sun Pharma shares gained after a U.S. court lifted an injunction, clearing the way for the launch of LEQSELVI, its drug for ...

TCS, Adani Energy Solutions, Tata Steel, BPFC, BHEL, Glenmark Pharma, Sun Pharma, Biocon, Bharti Hexacom, Bansal Wire, Taj ...